Indian drugmakers Lupin Ltd., Sun Pharmaceutical Industries and Glenmark Pharmaceuticals Ltd. are recalling various drugs from the U.S. market for a variety of reasons.
As per the latest Enforcement Report published by the U.S. Food and Drug Administration, Lupin is voluntarily recalling 55,000 vials and over 1.6 lakh boxes of anti-bacterial drug Ceftriaxone for injection in various strengths.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
The recall has been initiated by Lupin Pharmaceuticals, Inc., a subsidiary of the Mumbai-based firm. The products have been manufactured at the company's facility in Mandideep, Madhya Pradesh. The company is recalling specific lots of drugs due to the presence of particulate matter.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
"Product complaints received of grey flecks, identified as shredded rubber particulate matter from the stopper observed in reconstituted vials," U.S. FDA said. The ongoing voluntary nationwide recall has been classified as Class-I. Such recalls are for dangerous or defective products that predictably could cause serious health problems.
Lupin Pharmaceuticals is also recalling 2.8 lakh bottles of Cefdinir for Oral Suspension, used to treat bacterial infections, under Current Good Manufacturing Practice deviations.
The U.S. FDA has classified it as a Class-II recall, which is initiated in a "situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.”
Similarly, Sun Pharma is voluntarily recalling 13,918 cartons and over 1.39 lakh vials of Vecuronium Bromide for Injection, used as part of general anesthesia, due to presence of particulate matter.
Besides, Glenmark Pharmaceuticals is recalling 96,240 applicators of its product Estradiol Vaginal Inserts for defective delivery system. The U.S. FDA has termed it as a Class-II recall.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
